Aventis Pharma S.a.

Sanofi

Aventis Pharmaceuticals Inc.

Francois Clerc

Jean-Christophe Carry

Frank Halley

Herve Bouchard

Laurent Schio

Patrick Mailliet

Conception Nemecek

Marie-Pierre Cherrier

Chantal Carrez

Cecile Combeau

Michel Tabart

Michael L Edwards

Andrew David Morley

Fabrice Viviani

Dominique Damour

Michel Cheve

Fabienne Thompson

Tahir Nadeem Majid

Paul Joseph Cox

Charles J Gardner

Catherine Souaille

Timothy A Gillespy

Shelley Amendola

Brian L Pedgrift

Bernard Baudoin

Dorothea Kominos

Christopher D Edlin

Laurence Gauzy-Lazo

Odile Angouillant-Boniface

Justine Yeun Quai Lai

Olivier Houille

Sylvette Lachaud

Daniel N A Bezard

Sylvie Gontier

Teresa Damiano

Alain Krick

Serge Mignani

Alain Commercon

Bruno Filoche-Romme

Gilles Doerflinger

Jacques Mauger

Hervé Bouchard

Stephanie Deprets

Anil Nair

Hervé Minoux

Kirsten Bjergarde

Bruno Filoche-Rommé

Stéphanie Deprets

Claude E Barberis

Dominique Barbalat-Damour

Francois Hamy

Isabelle Depaty

Manfred Roesner

Stephanie D Deprets

Nina Ma

The invention relates to a compound of formula (I), more specifically in the levorotatory form (1a) thereof, in particular the form having a rotatory power [&#x3b1;]D=&#x2212;38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound may be in the form of a base or an acid addition salt, in particular a pharmaceutically acceptable acid. The compound is a selective Aurora A and B kinase inhibitor and can be used as an anticancer drug.

Anti-cancer compound and pharmaceutical composition containing the same

The invention relates to a compound of formula (I), more specifically in the levorotatory form (1a) thereof, in particular the form having a rotatory power [&#x3b1;]D=&#x2212;38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound may be in the form of a base or an acid addition salt, in particular a pharmaceutically acceptable acid. The compound is a selective Aurora A and B kinase inhibitor and can be used as an anticancer drug. 

This invention relates to compounds of formula (I) to processes for the preparation of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment comprising administering of such compounds.

1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them

This invention relates to benzimidazole and benzothiazole compounds of formula (I) to methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and to methods of treatment comprising administering of such compounds.

Benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use especially as c-MET inhibitors

The invention is directed to physiologically active compounds of general formula (I):&#x2014; and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles for inhibiting aurora2 and other kinases

The present invention concerns hydrazinocarbonyl-thieno[2,3-]pyrazoles of formula (I): wherein R1, R3, R4, are R5 are as defined in the disclosure; their preparation method, compositions containing the same and their use for the treatment of pathological conditions, in particular as anticancer agents.

Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof

The present invention relates in particular to novel chemical compounds, particularly to novel organophosphorus derivatives of indazoles, to the compositions containing them, and to the use thereof as medicinal products for treating cancers.

Organophosphorus derivatives of indazoles and use thereof as medicinal products

Substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines, compositions comprising them and use. The present invention relates in particular to novel substituted tetrahydro-1H-pyrazolo[3,4-c]pyridines having therapeutic activity, which can be used in particular in oncology. 

[object Object]

Substituted tetrahydro-1H-pyrazolo [3,4-c] pyridines, compositions comprising them, and use

The present invention discloses and claims benzimidazole compounds of formula (I):in which A is aryl or heteroaryl; Ris selected from optionally substituted alkyl, alkoxy, aryl or heteroaryl, NH-lower alkyl or NH-cycloalkyl, or halogen, NH; 1-imidazolyl or SOMe; Ris selected from optionally substituted &#x2014;CO-alkyl, &#x2014;CO-cycloalkyl, &#x2014;CO-aralkyl, &#x2014;CO-aryl, &#x2014;CO-alkoxy, aryl or aralkyl, or &#x2014;CO-amino, CO&#x2014;NHRor CO&#x2014;RRwherein Rand Rare selecteded independently from hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, fluoroalkyl, alkynyl, heteroalkyl, alkylheteroalkyl, aryl, aralkyl or together form an alkylene chain optionally containing one to 4 heteroatoms; a pharmaceutically acceptable salt or a prodrug thereof; the use of compounds of formula (I) for the treatment of cancer, and pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents.

Substituted benzimidazole compounds and their use for the treatment of cancer

The invention is directed to physiologically active compounds of general formula (I):and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles

Growing community of inventors

Antony, France

Francois Clerc